Cancer Archives

cancer shutterstock immunotherapy deep science ventures

News and Trends 2 Aug 2022

IDRx launches with $122M to treat cancer with precision combination therapies

DRx, Inc., a clinical-stage biopharmaceutical company, launched today with a $122 million oversubscribed series A financing. The financing was led by Andreessen Horowitz (a16z) and Casdin Capital, with participation from Nextech Invest, Forge Life Science Partners and other undisclosed investors. Inspired by a few curative combination regimens in cancer and the successful drug cocktails engineered […]

August 2, 2022 - 2 minutesmins - By Jim Cornall

Sanofi drops amcenestrant clinical development program

News and Trends 2 Aug 2022

Defence Therapeutics says AccuTOX kills cancer cells

Defence Therapeutics Inc., a Canadian biopharma company specializing in immune-oncology vaccines and drug delivery technologies, says it has discovered a novel DNA damaging function triggered by one of its lead compounds AccuTOX, which effectively elicits cell death in cancer cells. Cancer can be generally described as a state of uncontrolled cell proliferation. This is mainly […]

August 2, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

Glycostem and medac sign deal on AML and MM product

Glycostem Therapeutics B.V. and medac GmbH are to partner to commercialize Glycostem’s lead product, oNKord. oNKord is currently in a phase 1/2 clinical trial across 10 hospitals in five European countries. Glycostem is a Dutch clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf natural killer (NK) cells, and medac is an international pharmaceutical […]

August 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

Cellectis gets green light for non-Hodgkin lymphoma trial

French-headquartered gene-editing biotech company Cellectis says the U.S. Food and Drug Administration (FDA) has cleared Cellectis’ Investigational New Drug (IND) application to initiate a phase 1/2a clinical trial of UCART20x22 for patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL). The company plans to begin enrolling patients in the NatHaLi-01 study in the second half […]

August 2, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

SNIPR Biome announces new patent granted for applications targeting E. coli infections

SNIPR Biome has today (August 2) announced that it has been granted a patent for medical applications supporting the company’s lead program – a bacteriophage cocktail targeting E.coli infections. Granted by the US Patent and Trademark Office (USPTO), the patent adds to its intellectual property portfolio that contains more than 20 granted patents in the […]

August 2, 2022 - 2 minutesmins - By Liza Laws

News and Trends 1 Aug 2022

FDA puts clinical hold on Beam Theraputics’ cancer therapy

Beam Therapeutics Inc., a U.S. biotech company developing precision genetic medicines through base editing, says the company was informed via email last week that the U.S. Food and Drug Administration (FDA) has placed a hold on the BEAM-201 Investigational New Drug (IND) application for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T cell lymphoblastic […]

August 1, 2022 - 2 minutesmins - By Jim Cornall

Ryvu Therapeutics bags €22M from EIB to work on new cancer treatments

News and Trends 1 Aug 2022

Ipsen and Marengo Therapeutics partner to push immuno-oncology candidates into the clinic

Ipsen and Marengo Therapeutics, Inc. have announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic. Ipsen also announced it is exercising its option to acquire exclusive worldwide rights to an investigational ERK (extracellular signal-regulated kinase) inhibitor, discovered by AGV Discovery. Ipsen and Marengo Therapeutics details The collaboration between […]

August 1, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 1 Aug 2022

Immutep reports positive data from cancer study

Immutep Limited, an Australian biotech company developing LAG-3-related immunotherapy treatments for cancer and autoimmune disease, has announced new interim data from second-line NSCLC (non-small cell lung cancer) patients (Part B) in its phase 2 TACTI-002 trial. The data was presented at the IASLC 2022 World Conference of Lung Cancer (WCLC 2022) in Vienna, Austria, and […]

August 1, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 1 Aug 2022

Clinical hold on trial for colorectal cancer drug lifted by FDA

A clinical hold has been lifted by the US Food and Drug Administration (FDA) on a trial for a treatment for colorectal cancer after changes were made by the company responsible. Belgium-based Celyad Oncology SA is a clinical biotech company focused on finding and developing chimeric antigen receptor T cell (CAR T) therapies for cancer. […]

August 1, 2022 - 2 minutesmins - By Liza Laws

More News! 29 Jul 2022

Cancer patients enrolled on study to predict immunotherapy response

An observational study has started enrolling patients with advanced/metastatic non-small cell lung cancer (NSCLC). Florida-based Nilogen Oncosystems made the announcement today (July 29) that those who are receiving immune checkpoint inhibitors in the standard of care will be registered for the study. Using advanced artificial intelligence and machine learning algorithms to discover biomarker signatures as […]

July 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 29 Jul 2022

VerImmune raises $2.5M to develop virus-inspired particle immunotherapies

VerImmune, Inc., a U.S. biotech company developing new therapeutic modalities that aim to redirect the body’s pre-existing immunity toward cancer, has obtained $2.5 million in seed funding. The round was led by SeedFolio, a seed series venture capital firm. The round also included participation from U.S. and global investment venture firms such as Ulu Ventures, […]

July 29, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 29 Jul 2022

Biotech startup Novasenta raises $40M to advance novel cancer therapeutics

Novasenta Inc., a U.S. startup biotech company focused on the discovery and validation of novel targets to develop cancer therapies, has completed $40 million in Series A financing. The round was led by UPMC Enterprises. The funding will allow Novasenta to advance its pipeline of antibody-based therapeutics and expand its computational platforms for target discovery, […]

July 29, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

IDRx launches with $122M to treat cancer with precision combination therapies

Defence Therapeutics says AccuTOX kills cancer cells

Glycostem and medac sign deal on AML and MM product

Cellectis gets green light for non-Hodgkin lymphoma trial

SNIPR Biome announces new patent granted for applications targeting E. coli infections

FDA puts clinical hold on Beam Theraputics’ cancer therapy

Ipsen and Marengo Therapeutics partner to push immuno-oncology candidates into the clinic

Immutep reports positive data from cancer study

Clinical hold on trial for colorectal cancer drug lifted by FDA

Cancer patients enrolled on study to predict immunotherapy response

VerImmune raises $2.5M to develop virus-inspired particle immunotherapies

Biotech startup Novasenta raises $40M to advance novel cancer therapeutics

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!